Navigation Links
PregLem Announces Positive Phase III Results for Esmya(TM)

GENEVA, Switzerland, June 3, 2010 /PRNewswire/ --

- PEARL I Trial Meets Primary Efficacy and Safety Endpoints

- PregLem Preparing for Submission to the European Medicines Agency in 2010

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

The final set of positive Phase III results, combined with the positive PEARL II results announced in May 2010, will enable PregLem to submit a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) by the end of 2010. Upon approval, PregLem expects to launch the product in major European markets.

Ernest Loumaye, CEO & Co-Founder of PregLem, said:

"These results are another important milestone in PregLem's growth strategy. With positive results from two independent Phase III studies on our lead candidate, we now have the opportunity to move the company forward from its current focus on drug development towards our ambition of becoming a self-sustaining specialty biopharmaceutical company. Our immediate focus is on preparing the MAA dossier. However, we are simultaneously leveraging our unique research and market insight to start preparing for the launch of Esmya, our first product in Europe."

Key Phase III results

PEARL I was designed to demonstrate superior efficacy of Esmya versus placebo for the treatment of symptomatic uterine fibroids in women with heavy bleeding leading to anaemia. It was a randomised, parallel group, double-blind, placebo-controlled, multi-centre study with a total of 242 patients. It compared 5mg and 10mg doses of Esmya and placebo once daily for three months with concomitant iron administration in all three arms.

The study met its two co-primary efficacy endpoints. Esmya demonstrated statistically significant superior efficacy to placebo in reducing excessive uterine bleeding measured as a percentage of patients with a reduction of PBAC (Pictorial Blood Assessment Chart) score lower than 75 and in reduction of total fibroids volume assessed by centralised MRI reading.

Esmya also showed superior efficacy to placebo in correcting anaemia caused by uterine fibroids and suppressing fibroids-related pain using the McGill Short Form questionnaire (SF-MPQ). Both the PBAC and SF-MPQ are validated self-reporting tools.

Ernest Loumaye added:

"The combined PEARL I and II data shows that Esmya has the potential to be the first effective medical treatment for this condition, with no serious side effects, for millions of women around the world."

Professor Tetyana Tatarchuk, the Principal investigator from the Institute of Obstetrics and Gynaecology in City Clinical Hospital (Ukraine), said:

"These data are very convincing. A medical treatment for alleviating the symptoms related to fibroids and reducing the fibroids volume would be very useful in our day-to-day management of this significant and distressing condition. These results clearly illustrate the potential for Esmya to offer an effective and well tolerated treatment for this condition."

Uterine fibroids affect approximately 40% of women between the ages of 35 and 55, including 24 million women in Europe and over 20 million women in North America. The condition is characterised by excessive uterine bleeding, anaemia, pain and infertility. It significantly impairs the quality of life for many women, leading in many cases to a hysterectomy. There are no effective, well tolerated medical treatments available. GnRH agonists are the only approved treatment of symptomatic uterine fibroids but their use has been relatively limited due to their side effect profile which causes suppression of oestrogen to castration levels, resulting in hot flushes, depression, mood swings, loss of libido, vaginitis and loss of bone mineral density.

About PregLem

PregLem is a European speciality biopharmaceutical company dedicated to the development and commercialization of a new class of drugs for women's reproductive health conditions. PregLem has an experienced senior management team, with a proven track record in developing, registering and commercialising reproductive health products. The company is backed by a blue chip investor base.

Visit for more information.

About Esmya(TM)

Ulipristal acetate is a first-in-class, orally active selective progesterone receptor modulator which reversibly blocks the progesterone receptors in target tissues.

PregLem's Phase III programme for Esmya consists of two separate, parallel, randomised, double-blind studies identified as PEARL I and PEARL II. Together the Phase III trials involved 540 patients in 14 countries at 5mg and 10mg doses.

    For further information, please contact:

    Désirée Andrey
    CEO Office
    PregLem SA
    Tel: +41(0)22-884-03-40

    Capital MS&L:
    Mary Clark, Anna Davies
    Tel: +44(0)20-7307-5330

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):